Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

- Male/Females at least 20 years of age. - Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control. - Females have a negative pregnancy test at screening. - Diagnosis of RA and met ACR criteria. - Must discontinue any TNF at least 2 months prior to baseline. - In condition of general good health.

- History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix. - History of current acute inflammatory joint disease. - Use of TAMIFLU or Symmetrel within 3 months of study drug administration. - Recent (3 month) history of influenza or pneumococcal bacterial infection. - Known positive human immunodeficiency virus (HIV) status. - Positive hepatitis B or hepatitis C virus. - Positive PPD >5 mm. - Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.